Human Oversight and Automation Bias

#Human presence is not enough

IMDRF places emphasis on the performance of the human-AI team in the intended use environment. This includes users' skills, understanding of outputs and limitations, potential overreliance and user error. Simply including a person in a diagram does not show how those interactions work.

Read who the users are, what they are expected to do with an output, what information they receive and how that arrangement was evaluated. Effective oversight is a property of the combined people, tool and workflow, not a label that follows automatically from requiring someone to review a result.

Evidence: IMDRF: good machine learning practice principles (2025) / FDA, Health Canada and MHRA: device transparency principles

#Understand the risk of overreliance

Goddard and colleagues define automation bias as the tendency to over-rely on automation. Their systematic-review abstract describes user experience, trust and confidence as possible influences, alongside environmental factors such as workload, task complexity and time constraints. Decision support can help performance while still introducing new errors.

This older review draws on several research fields, not only present-day clinical AI. It does not supply a universal error rate for a new product. Use it to understand why reliance needs evaluation, not to assume that every automated output is wrong or that every human override is right.

Evidence: Goddard and colleagues: automation bias review, abstract

#Make information usable at the right moment

The transparency principles describe information about intended use, performance, benefits, risks, known limitations and gaps in data. They also consider where and when to present that information, including workflow stages, updates and newly discovered risks. Different users may need different levels of detail.

Clear communication can support critical assessment, but providing more text is not the same as proving that users understand it. Human-centered design considers users, environments and workflows through development and evaluation. An explanation should help a relevant decision, not act as a decorative assurance of safety.

Evidence: FDA, Health Canada and MHRA: device transparency principles

#Check the oversight in actual use

DECIDE-AI emphasizes human factors in early live clinical evaluation, including how people and a decision-support system interact. The paper notes that even preclinical human-factors evaluation cannot reliably identify every issue that may arise in a live clinical environment.

Finlayson and colleagues describe combining technical oversight with clinicians' concerns and a way to report possible failures. Read whether the study or service examined that process, rather than assuming an escalation label worked. This is general education, not a claim that Mynd has a clinical AI oversight team or an operating safety-monitoring service.

Evidence: DECIDE-AI: reporting early clinical evaluation / Finlayson and colleagues: the clinician and dataset shift

Source note

The sections above were checked against the linked sources. No clinical review has been performed. This is general research education, not a clinical guideline.